Analyst Samantha Semenkow Maintains Bullish Rating on Spyre Therapeutics

Analyst Samantha Semenkow has reaffirmed a bullish rating on Spyre Therapeutics (SYRE), maintaining a price target of $119. This update indicates a positive outlook for the company's stock as reported on October 21, 2026.